Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Group 1 - Corvus Pharmaceuticals, Inc. has completed an upsized underwritten public offering of 9,085,778 shares at a price of $22.15 per share, resulting in gross proceeds of approximately $201.2 million before deductions [1][2] - The net proceeds from the offering are expected to be used for working capital and general corporate purposes, including capital expenditures and research and development for various clinical trials [2] - Jefferies and Goldman Sachs & Co. LLC served as lead book-running managers for the offering, with Mizuho as bookrunner and Ladenburg Thalmann as co-manager [3] Group 2 - A shelf registration statement related to the securities sold in this offering was declared effective by the SEC on August 15, 2024, and a related registration statement was filed on January 21, 2026 [4] - The offering was made only by means of a prospectus supplement and accompanying prospectus, which are available on the SEC's website [4] Group 3 - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new approach to immunotherapy for various immune diseases and cancer [6] - The company's lead product candidate, soquelitinib, is being evaluated in a Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for atopic dermatitis [6]